Business Description
Tianjin Tianyao Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
No. 109 Bawei Road, Hedong District, Tianjin, Tianjin, CHN, 300171
Compare
Compare
Traded in other countries / regions
600488.China
Description
Tianjin Tianyao Pharmaceutical Co Ltd is a China-based company engages in the development, manufacture, distribution, and export of pharmaceutical products. Its products include corticosteroids and cardiovascular medicine, dexamethasone, and cortisone acetate.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.19 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | 9.27 | |||||
| Interest Coverage | 4.11 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 16 | |||||
| 3-Year EBITDA Growth Rate | 3.4 | |||||
| 3-Year EPS without NRI Growth Rate | -30.3 | |||||
| 3-Year FCF Growth Rate | -24.4 | |||||
| 3-Year Book Growth Rate | 0.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.7 | |||||
| 9-Day RSI | 39.08 | |||||
| 14-Day RSI | 42.41 | |||||
| 6-1 Month Momentum % | 4 | |||||
| 12-1 Month Momentum % | 6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | |||||
| Quick Ratio | 0.49 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 181.3 | |||||
| Days Sales Outstanding | 50.16 | |||||
| Days Payable | 106.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.33 | |||||
| Dividend Payout Ratio | 0.23 | |||||
| 3-Year Dividend Growth Rate | -34.8 | |||||
| Forward Dividend Yield % | 0.33 | |||||
| 5-Year Yield-on-Cost % | 0.24 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.38 | |||||
| Operating Margin % | 5.15 | |||||
| Net Margin % | 1.21 | |||||
| ROE % | 1.52 | |||||
| ROA % | 0.72 | |||||
| ROIC % | 2.62 | |||||
| ROC (Joel Greenblatt) % | 3.85 | |||||
| ROCE % | 3.51 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 98.84 | |||||
| PE Ratio without NRI | 98.84 | |||||
| Shiller PE Ratio | 41.11 | |||||
| PEG Ratio | 11.91 | |||||
| PS Ratio | 1.22 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Tangible-Book | 1.76 | |||||
| Price-to-Operating-Cash-Flow | 15.4 | |||||
| EV-to-EBIT | 37.75 | |||||
| EV-to-EBITDA | 37.75 | |||||
| EV-to-Revenue | 1.54 | |||||
| EV-to-FCF | -108.6 | |||||
| Price-to-Projected-FCF | 2.61 | |||||
| Price-to-Median-PS-Value | 0.55 | |||||
| Price-to-Graham-Number | 2.76 | |||||
| Earnings Yield (Greenblatt) % | 2.65 | |||||
| Forward Rate of Return (Yacktman) % | -7.23 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,791.753 | ||
| EPS (TTM) (¥) | 0.043 | ||
| Beta | 0.7 | ||
| Volatility % | 33.65 | ||
| 14-Day RSI | 42.41 | ||
| 14-Day ATR (¥) | 0.101721 | ||
| 20-Day SMA (¥) | 4.364 | ||
| 12-1 Month Momentum % | 6 | ||
| 52-Week Range (¥) | 3.77 - 5.24 | ||
| Shares Outstanding (Mil) | 1,100.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tianjin Tianyao Pharmaceutical Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||